title: Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study.
abstract: OBJECTIVE
  Although aspirin has been widely prescribed for the prevention of cardiovascular events, its risk of gastrointestinal complications is of great concern. Despite expectations for such, few data are available on the prevalence or incidence of gastrointestinal complications in aspirin users in Japan. The Management of Aspirin-induced GastroIntestinal Complications (MAGIC) is the first attempt at collaboration among cardiologists, neurologists, and gastroenterologists to obtain such findings. We aim to share all about the MAGIC study.
  
  
  METHODS
  The MAGIC is a prospective cohort study involving patients taking low-dose aspirin (81 mg to 325 mg per day) for longer than 1 month. Participants are recruited from multiple disease categories, including those with coronary artery disease, cerebrovascular disease, atrial fibrillation, and other cardiovascular conditions requiring antithrombotic therapy. Its duration of follow-up is 1 year. At baseline and 1 year follow-up, all participants will undergo endoscopic examination. The primary outcome is upper gastrointestinal complications, classified as erosions, ulcers, and bleeding. Secondary outcomes include LANZA score, non-fatal cardiovascular events, any bleeding, cancer, and death.
  
  
  RESULTS
  1,533 participants were entered in the MAGIC cohort. By underlying disease, about 45% of them had coronary artery diseases, followed by cerebrovascular diseases (35%), atrial fibrillation (10%) and other cardiovascular diseases (10%).
  
  
  CONCLUSIONS
  The MAGIC study will yield important findings with regard to the prevalence and incidence of gastrointestinal complications and related risk factors for low-dose aspirin users. It may also report that use of anti-secretory agents such as proton pump inhibitors reduces the risk of such complications.
authors.affiliation: Division of Biostatistics and Clinical Epidemiology, University of Toyama, Japan. horigasa@las.u-toyama.ac.jp
authors.forename: Hideki
authors.initials: H
authors.lastname: Origasa
authors.forename: Shinya
authors.initials: S
authors.lastname: Goto
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shimada
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Uchiyama
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Okada
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sugano
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Hiraishi
authors.forename: Naomi
authors.initials: N
authors.lastname: Uemura
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D015340:Epidemiologic Research Design; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D007564:Japan; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D014652:Vascular Diseases / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control
chemical_list: D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D001241:Aspirin